Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome.

Gut · 2011 · PMC3112364 · PMID 21317170

Europe PMC DOI

hedged sentence

0.0510

closest p · 1.0× alpha

0.0510

boldest claim

The sentences

of borderline significancep=0.051so close (0.05 < p ≤ 0.1)

However, reductions in parenteral volume and the composite effects were still only of borderline significance compared with placebo (p=0.051 and p=0.07, respectively).

also in 2,624 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.